Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis
Executive Summary
The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.
You may also be interested in...
Takeda Raises Full-Year Outlook On Strong Mainstays
Japan's largest pharma firm logs what was generally viewed by analysts as a solid fiscal third quarter, driven by growth for its portfolio of global products, leading to raised guidance for the full year despite one pipeline setback. There will also be multiple C-suite reshuffles come 1 April.
Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.
Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.